SecBot SecBot
20-F ·Filed Apr 20, 2026

BRSYF

Brainsway Ltd.
BULLISH
Impact 7/10
Horizonmonths Processed7mo ago SEC0001171843-26-002568
Notable filing: 20-F
Actionable Insight ▲ Bullish

Monitor the resolution of the Magnus Medical patent dispute, as an unfavorable outcome could impact the commercialization of the newly cleared accelerated treatment protocol. The company's heavy reliance on a single customer (significant portion of revenue) represents a concentration risk that investors should track in future quarters.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$13.55
T+0 close · Apr 20, 2026 · via day close
Latest settled
+11.66%
T+60 · $15.13
Vs SPY
+4.76%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 21 $13.55entry
  2. T+1 · 7mo ago 0.00%α −1.02% · $13.55
  3. T+5 · 7mo ago 0.00%α −1.08% · $13.55
  4. T+20 · 6mo ago +24.28%α +19.37% · $16.84
  5. T+60 · 4mo ago +11.66%α +4.76% · $15.13

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Brainsway's 20-F filing for 2025 shows strong financial growth with a 27% revenue increase to $52.2 million and net income of $7.6 million, driven by U.S. market expansion and new FDA clearances. The company's strategic investments in MSOs and Neurolief, along with a significant $20 million private placement, position it for continued growth, although its reliance on a single large customer and ongoing patent litigation with Magnus Medical present notable risks.

Key Facts

  • Revenue increased 27.3% YoY to $52.2 million for 2025, with net income of $7.6 million
  • U.S. revenue grew 33% to $44.2 million, now representing 85% of total revenue
  • Received FDA clearance for adolescent MDD treatment (ages 15-21) and accelerated treatment protocol
  • Completed $20 million private placement with Valor in November 2024
  • Invested $9.8 million in MSOs (Axis, Tangient, Stella) and $11 million in Neurolief
  • Faced patent infringement claim from Magnus Medical regarding accelerated TMS protocol

Financial Impact

Revenue of $52.2 million (+27.3% YoY) and net income of $7.6 million (+162% YoY)

revenuenet incomedilution

Risk Factors

  • Patent infringement lawsuit from Magnus Medical
  • High customer concentration risk with a single customer
  • Geopolitical risks from operations in Israel

Market Snapshot

Exchange
OTC
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 12 SEC documents filed with EDGAR.

DocumentAccession Number
20-F Filing (Primary)0001171843-26-002568
Exhibit: exh_23.htm0001171843-26-002568
Exhibit: exh_424.htm0001171843-26-002568
Exhibit: exh_421.htm0001171843-26-002568
Exhibit: exh_121.htm0001171843-26-002568
Exhibit: exh_122.htm0001171843-26-002568
Exhibit: exh_151.htm0001171843-26-002568
Exhibit: exh_13.htm0001171843-26-002568
Exhibit: exh_8.htm0001171843-26-002568
Document: 0001171843-26-002568-index-headers.html0001171843-26-002568
Document: 0001171843-26-002568-index.html0001171843-26-002568
Document: 0001171843-26-002568.txt0001171843-26-002568

Track record

5 reports on BRSYF

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +24.28% at T+20 after the Apr 15, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Jun 9, 202622w ago 6-K Bullish 7/10 Entry $16.84 to $15.13 Now $10.62 −36.94% ▼ −10.15% −14.24% vs SPY
  2. May 18, 202626w ago 6-K Neutral 4/10 Entry $16.84 to $15.13 Now $10.62 −36.94% ▼ −10.15% −15.01% vs SPY
  3. May 13, 202626w ago 6-K Bullish 8/10 Entry $16.84 to $15.13 Now $10.62 −36.94% ▼ −10.15% −14.59% vs SPY
  4. Apr 20, 202630w ago 20-F Bullish 7/10 Viewing Entry $13.55 to $15.13 Now $10.62 −21.62% ▲ +11.66% +4.76% vs SPY
  5. Apr 15, 202630w ago 6-K Bullish 7/10 Entry $13.55 to $15.13 Now $10.62 −21.62% ▲ +11.66% +3.52% vs SPY
Showing 5 of 5

US Market Status

Market Closed · Opens in 9h 11m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 20, 2026